My diet for a healthy liver came from my doctor and a nutritionist
If you’re like me, there’s no shortage of well-meaning folks who, upon hearing that we’re sick, are eager to help. Perhaps they’ll turn to “Dr.
Fatty liver disease
MASLD tied to higher mortality risk from nearly every cause
Compared with the general population, the risk of death is nearly twice as high in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…
LiverMultiScan may lessen need for biopsy in assessing MASLD
Perspectum‘s MRI-based LiverMultiScan improves the diagnostic rate of metabolic dysfunction-associated steatotic liver disease (MASLD) — a form of fatty liver disease —…
Having friends to share my disease with, so we will go farther together
When I first learned that my liver was failing, I didn’t know anyone who had what I had: cirrhosis from fatty liver disease, specifically,…
Icosabutate fails MASH Phase 2 trial but shows some benefits in liver
Northsea Therapeutics’ oral therapy candidate icosabutate was not superior to a placebo at resolving metabolic dysfunction-associated steatohepatitis (MASH) — a severe form of…
Efruxifermin reverses MASH-related cirrhosis in Phase 2 trial
Treatment with Akero Therapeutics’ investigational efruxifermin led to reversals of compensated cirrhosis, or irreversible scarring in a still-functioning liver, among adults with metabolic dysfunction-associated…
Rezdiffra reduces scarring in MASH with compensated cirrhosis: Trial
Long-term treatment with Rezdiffra (resmetirom) reduces liver scarring for most people with compensated cirrhosis, or irreversible scarring in a still-functioning liver, due to metabolic…
I didn’t pay attention to my health until it took a turn for the worse
Groundhog Day is probably my favorite holiday. It’s pretty noncontroversial, really. Unless you really hate winter, you probably don’t have any problems with Punxsutawney Phil…
Algorithm spots people with MASLD, MASH using health records
Researchers have developed an algorithm to identify people with metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver disease, based on information…
Phase 2 trial of DD01 in treating MASH completes enrollment
D&D Pharmatech has finished enrolling a Phase 2 clinical trial of its experimental therapy DD01 in overweight or obese adults with metabolic dysfunction-associated steatohepatitis…
